Compare · AIMD vs NVO
AIMD vs NVO
Side-by-side comparison of Ainos Inc. (AIMD) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AIMD and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 17391.6x AIMD ($12.4M).
- Both names hit the wire about 9 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 0 for AIMD).
- Company
- Ainos Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $12.4M
- $215.46B
- 1M return
- +0.00%
- -
- 1Y return
- -63.80%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AIMD
- Ainos Launches Atmosphere Engine, Extending Physical AI from Environmental Sensing to Active Environmental Management
- Ainos Unveils Next-Generation AI Nose, Advancing the Infrastructure for Chemical Intelligence
- Ainos Surpasses 878 Million Real-World Data Points, Up 43% in 23 Days as 1,400-System AI Nose Semiconductor Deployment Advances
- Ainos to Showcase Environmental Intelligence for Physical AI at SEMICON Taiwan 2026
- VASRO Research Highlights Ainos' Progress in Scaling Smell AI Commercialization and Compounding Its Smell ID Dataset
- Zacks Small-Cap Research Covers Ainos' AI Nose Platform and Expansion of Smell AI Applications
- Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ainos Reports Second Quarter 2026 Results and Highlights Continued AI Nose Execution Across Industrial, Healthcare Infrastructure and Robotics Markets
- SEC Form 10-Q filed by Ainos Inc.
- SEC Form 424B5 filed by Ainos Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S